GlassScriptPhysician profile
Jennifer Harrison
NPI 1881251189
$4,996.21
in general payments reported to CMS, 2019-2025
22 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,256 · 2022: $1,445 · 2023: $1,420 · 2024: $732 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,461.61 | 2021-2025 | |
| Alkermes, INC. | $942.24 | 2021-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $615.97 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $301.44 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $285.51 | 2021-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $210.14 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $202.03 | 2022-2025 | Auvelity |
| Lundbeck LLC | $183.06 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $135.62 | 2022-2023 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $110.38 | 2021-2024 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $81.65 | 2023-2024 | Quviviq |
| Amgen INC. | $80.55 | 2021 | |
| Jazz Pharmaceuticals INC. | $80.40 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.92 | 2021-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $48.66 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $40.44 | 2022 | |
| Tris Pharma INC | $34.15 | 2022-2024 | Dyanavel Xr |
| Corium, LLC | $29.62 | 2022-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $26.07 | 2021-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $17.96 | 2021 | |
| Adlon Therapeutics L.P. | $17.46 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.